BACKGROUND: Non-adherence to treatment remains a major obstacle to efficient tuberculosis control in developing countries. The dual infection of Tuberculosis and HIV presents further adherence problems because of high pill burden and adverse effects. This poses a risk of increased multi-drug resistant TB. However, the prevalence of non-adherence and its associated factors have not been studied in these patients in Uganda. OBJECTIVES: To determine the prevalence and factors associated with non-adherence to anti-TB drugs among TB/HIV co-infected patients in Mbarara hospital. METHODS: A cross-sectional study with qualitative and quantitative data collection methods was conducted among TB/HIV co-infected adults in Mbarara hospital from January to March 2008. Consecutive sampling was used to select 140 participants. Adherence was assessed over a 5-day period prior to the interview using patients self-reports. Data was collected using an interviewer administered questionnaire. Qualitative data was collected through key informant interviews using a topic guide and was analyzed manually. Quantitative data was analyzed using STATA version 8. Logistic regression was used to determine factors associated with nonadherence. RESULTS: The prevalence of non-adherence was 25% (95% CI=17.8-32%). Being on continuous phase of the TB regimen was significantly associated with non-adherence (OR=6.24, p<0.001). Alcohol consumption, being on antiretroviral therapy and smoking confounded the relationship between stage of the TB regimen and non-adherence. CONCLUSION: The prevalence of non-adherence was high. Patients that are on continuous phase of TB treatment should be supported to continue taking their drugs. In addition, patients that drink alcohol; smoke and those not on ART should be targeted with interventions to improve adherence.
BACKGROUND: Non-adherence to treatment remains a major obstacle to efficient tuberculosis control in developing countries. The dual infection of Tuberculosis and HIV presents further adherence problems because of high pill burden and adverse effects. This poses a risk of increased multi-drug resistant TB. However, the prevalence of non-adherence and its associated factors have not been studied in these patients in Uganda. OBJECTIVES: To determine the prevalence and factors associated with non-adherence to anti-TB drugs among TB/HIV co-infectedpatients in Mbarara hospital. METHODS: A cross-sectional study with qualitative and quantitative data collection methods was conducted among TB/HIV co-infected adults in Mbarara hospital from January to March 2008. Consecutive sampling was used to select 140 participants. Adherence was assessed over a 5-day period prior to the interview using patients self-reports. Data was collected using an interviewer administered questionnaire. Qualitative data was collected through key informant interviews using a topic guide and was analyzed manually. Quantitative data was analyzed using STATA version 8. Logistic regression was used to determine factors associated with nonadherence. RESULTS: The prevalence of non-adherence was 25% (95% CI=17.8-32%). Being on continuous phase of the TB regimen was significantly associated with non-adherence (OR=6.24, p<0.001). Alcohol consumption, being on antiretroviral therapy and smoking confounded the relationship between stage of the TB regimen and non-adherence. CONCLUSION: The prevalence of non-adherence was high. Patients that are on continuous phase of TB treatment should be supported to continue taking their drugs. In addition, patients that drink alcohol; smoke and those not on ART should be targeted with interventions to improve adherence.
Authors: A L Gifford; J E Bormann; M J Shively; B C Wright; D D Richman; S A Bozzette Journal: J Acquir Immune Defic Syndr Date: 2000-04-15 Impact factor: 3.731
Authors: A Jaiswal; V Singh; J A Ogden; J D H Porter; P P Sharma; R Sarin; V K Arora; R C Jain Journal: Trop Med Int Health Date: 2003-07 Impact factor: 2.622
Authors: Tanuja N Gengiah; Andrew L Gray; Kogieleum Naidoo; Quarraisha Abdool Karim Journal: Expert Opin Drug Saf Date: 2011-01-05 Impact factor: 4.250
Authors: A C Miller; I Y Gelmanova; S Keshavjee; S Atwood; G Yanova; S Mishustin; J J Furin; S S Shin Journal: Int J Tuberc Lung Dis Date: 2012-04-09 Impact factor: 2.373
Authors: Julia V Ershova; Laura Jean Podewils; Liza E Bronner; Heather G Stockwell; Sicelo S Dlamini; Lerole D Mametja Journal: S Afr Med J Date: 2014-03-26
Authors: Abdallah Mkopi; Nyagosya Range; Fred Lwilla; Saidi Egwaga; Alexander Schulze; Eveline Geubbels; Frank van Leth Journal: PLoS One Date: 2012-12-19 Impact factor: 3.240
Authors: T Q Lo; J E Oeltmann; F O Odhiambo; C Beynon; E Pevzner; K P Cain; K F Laserson; P A Phillips-Howard Journal: Trop Med Int Health Date: 2013-04 Impact factor: 2.622